Population
Platelets and endothelial cells (in vitro and in vivo models)
Design
Review
Authors
Loading...
NO donors may substitute for deficient EDRF in platelet inhibition; leaves open randomized outcome trials before clinical adoption.
Nitric oxide donors can act as a substitute for deficient endothelial EDRF to suppress platelet aggregation.
E. Bassenge (1991) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: